Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β₂-agonists in patients with atopic asthma.

ABSTRACT:

Objectives

To evaluate the efficacy and safety of AZD1981, a potent, specific antagonist of the CRTh2 receptor, as add-on therapy to inhaled corticosteroids (ICS) and long-acting β₂-agonists (LABA), in patients with persistent asthma with an allergic component.

Patients and methods

In this placebo-controlled, parallel-group Phase IIb study, patients with persistent atopic asthma on ICS and LABA were randomized to receive 12 weeks of treatment with placebo or AZD1981 (80 mg daily, 200 mg daily, and 10 mg, 40 mg, 100 mg, or 400 mg twice daily [BID]). The primary end point was the mean change from baseline in predose, prebronchodilator forced expiratory volume in 1 second (FEV₁) averaged over weeks 2, 4, 8, and 12 in the AZD1981-treatment group vs the plac

SUBMITTER: Bateman ED 

PROVIDER: S-EPMC5942163 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature